RT Journal Article
T1 Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
A1 Ponde, Noam
A1 Bradbury, Ian
A1 Lambertini, Matteo
A1 Ewer, Michael
A1 Campbell, Christine
A1 Ameels, Helene
A1 Zardavas, Dimitrios
A1 Di Cosimo, Serena
A1 Baselga, José
A1 Huober, Jens
A1 Izquierdo, Miguel
A1 Fumagalli, Debora
A1 Bozovic-Spasojevic, Ivana
A1 Maetens, Marion
A1 Harbeck, Nadia
A1 Pusztai, Lajos
A1 Berghorn, Michael
A1 Im, Young-Hyuck
A1 Borrego, Manuel Ruiz
A1 Chen, Dar-Ren
A1 Rodeheffer, Richard
A1 Piccart, Martine
A1 Suter, Thomas
A1 de Azambuja, Evandro
K1 Brain natriuretic peptide
K1 Cardiotoxicity
K1 HER2 positive breast cancer
K1 Lapatinib
K1 Troponin T
AB Biomarkers of cardiac damages, such as troponin T (TnT) and the amino-terminal fragment of brain natriuretic peptide (NT-proBNP), may be useful as early predictors of cardiac dysfunction. The role of these biomarkers in patients receiving lapatinib and/or trastuzumab before anthracyclines is unknown. This study explores TnT and NT-proBNP as predictors of early cardiac toxicity in neoadjuvant breast cancer patients. This sub-study of the NEOALTTO trial tested if changes in the levels of TnT and NT-proBNP occurred after 2 weeks of anti-HER2 therapy (lapatinib, trastuzumab or their combination) alone and/or after 18 weeks of anti-HER2 therapy plus weekly paclitaxel. 173 and 172 were tested at all three timepoints for NT-proBNP and TnT, respectively. The incidence of biomarker elevation was overall low at all timepoints for all the three treatment arms. A total of 13 CEs in 11 patients occurred. Biomarker elevations in patients with CEs were very rare; only one patient with subsequent CE had a NT-proBNP elevation at baseline and at week 2. These results suggest that TnT and proBNP may not be useful as early predictors of cardiac toxicity in anthracycline-naïve patients receiving trastuzumab and/or lapatinib.
YR 2017
FD 2017-12-27
LK http://hdl.handle.net/10668/11951
UL http://hdl.handle.net/10668/11951
LA en
DS RISalud
RD Apr 5, 2025